Arturo Pujia1, Carmine Gazzaruso2, Tiziana Montalcini3. 1. Clinical Nutrition Unit, Department of Medical and Surgical Science, University Magna Graecia, Catanzaro, 88100, Italy. 2. Internal and Emergency Medicine and Center for Applied Clinical Research (Ce.R.C.A.) Clinical Institute "Beato Matteo", Vigevano, 27029, Italy. 3. Clinical Nutrition Unit, Menopause Clinic, Department of Clinical and Experimental Medicine, University Magna Graecia, Catanzaro, 88100, Italy. tmontalcini@unicz.it.
Abstract
PURPOSE: C-peptide secretion is deficient or absent in type 1 diabetes mellitus. It is well accepted that insulin replacement therapy cannot prevent the development of long-term diabetes-related complications, which can often be disabling or even life-threatening. Several cross-sectional investigations have suggested that residual C-peptide production in patients with type 1 diabetes mellitus would help prevent a number of complications. In animal models of diabetes and in patients with type 1 diabetes mellitus, C-peptide replacement improves renal function, skin and skeletal muscle blood flow, nerve conduction, glucose utilization, and other diabetes-related complications. Recent investigations suggest a new beneficial effect of C-peptide, which to date has never been studied. It is known that osteoporosis is the most prevalent short-term complication in type 1 diabetes mellitus. This review will highlight new insights into the pathophysiology and future therapeutic modalities for osteoporosis in individuals with diabetes. METHODS: This review provides a concise summary of old and new insights into the role of C-peptide in diabetes-related complications. RESULTS: The data suggest that C-peptide is a bioactive peptide, acting independently of insulin, which binds to a G-protein-coupled membrane binding site in different cell types. By triggering Ca2+-dependent intracellular signaling pathways, both Na+, K+-ATPase and endothelial nitric oxide synthase are activated. C-peptide may act on osteoblast cells by ERK 1/2 pathway activation, modulate collagen biosynthesis and RANKL expression. Furthermore, C-peptide-deficient postmenopausal women, not affected by diabetes, have a lower bone mineral density than those with normal C-peptide levels. CONCLUSION: Taken together these studies encourage further investigations to elucidate the role of C-peptide in preventing bone loss in type 1 diabetes mellitus and in those individuals with C-peptide deficiency and osteoporosis.
PURPOSE:C-peptide secretion is deficient or absent in type 1 diabetes mellitus. It is well accepted that insulin replacement therapy cannot prevent the development of long-term diabetes-related complications, which can often be disabling or even life-threatening. Several cross-sectional investigations have suggested that residual C-peptide production in patients with type 1 diabetes mellitus would help prevent a number of complications. In animal models of diabetes and in patients with type 1 diabetes mellitus, C-peptide replacement improves renal function, skin and skeletal muscle blood flow, nerve conduction, glucose utilization, and other diabetes-related complications. Recent investigations suggest a new beneficial effect of C-peptide, which to date has never been studied. It is known that osteoporosis is the most prevalent short-term complication in type 1 diabetes mellitus. This review will highlight new insights into the pathophysiology and future therapeutic modalities for osteoporosis in individuals with diabetes. METHODS: This review provides a concise summary of old and new insights into the role of C-peptide in diabetes-related complications. RESULTS: The data suggest that C-peptide is a bioactive peptide, acting independently of insulin, which binds to a G-protein-coupled membrane binding site in different cell types. By triggering Ca2+-dependent intracellular signaling pathways, both Na+, K+-ATPase and endothelial nitric oxide synthase are activated. C-peptide may act on osteoblast cells by ERK 1/2 pathway activation, modulate collagen biosynthesis and RANKL expression. Furthermore, C-peptide-deficient postmenopausal women, not affected by diabetes, have a lower bone mineral density than those with normal C-peptide levels. CONCLUSION: Taken together these studies encourage further investigations to elucidate the role of C-peptide in preventing bone loss in type 1 diabetes mellitus and in those individuals with C-peptide deficiency and osteoporosis.
Authors: N M Al-Rasheed; F Meakin; E L Royal; A J Lewington; J Brown; G B Willars; N J Brunskill Journal: Diabetologia Date: 2004-05-26 Impact factor: 10.122
Authors: Y Ido; A Vindigni; K Chang; L Stramm; R Chance; W F Heath; R D DiMarchi; E Di Cera; J R Williamson Journal: Science Date: 1997-07-25 Impact factor: 47.728
Authors: M Lunt; P Masaryk; C Scheidt-Nave; J Nijs; G Poor; H Pols; J A Falch; G Hammermeister; D M Reid; L Benevolenskaya; K Weber; J Cannata; T W O'Neill; D Felsenberg; A J Silman; J Reeve Journal: Osteoporos Int Date: 2001 Impact factor: 4.507
Authors: Amber S Kujath; Lauretta Quinn; Mary E Elliott; Tamara J LeCaire; Neil Binkley; Andrea R Molino; Kirstie K Danielson Journal: Diabetes Metab Res Rev Date: 2015-01-21 Impact factor: 4.876
Authors: Vladimir Kron; Miroslav Verner; Pavel Smetana; Jana Janoutova; Vladimir Janout; Karel Martinik Journal: J Appl Biomed Date: 2020-12-08 Impact factor: 1.797